SCHEMBL4101769

SCHEMBL4101769

O=C1N=CCN1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
F2 P00734 1/20 0.45
PLG P00747 1/20 0.45
ELANE P08246 1/20 0.45
CTSG P08311 1/20 0.45
CMA1 P23946 1/20 0.45
CTRC Q99895 1/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
GAA P10253 1/20 0.45
THRB P10828 1/20 0.45
POLB P06746 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9408653 0.73 SMN1; SMN2 (0.41) DDB1CRBNL3MBTL1KMT2AALDH1A1
SCHEMBL3948981 0.73 RAB9A (0.50) KMT2AMEN1GAALMNAKDM4E
SCHEMBL4892237 0.72 EPHX2 (0.45) DDB1CRBNL3MBTL1F2PLG
SCHEMBL8489644 0.72 DDB1 (0.45) DDB1CRBNL3MBTL1F2PLG
SCHEMBL5251526 0.72 DDB1 (0.49) DDB1CRBNL3MBTL1F2PLG
SCHEMBL29450073 0.71 KMT2A (0.76) DDB1CRBNL3MBTL1F2PLG
SCHEMBL16416392 0.71 KMT2A (0.76) DDB1CRBNL3MBTL1F2PLG
SCHEMBL11052192 0.71 KMT2A (0.59) DDB1CRBNL3MBTL1F2PLG
SCHEMBL1488276 0.71 L3MBTL1 (0.56) DDB1CRBNL3MBTL1F2PLG
SCHEMBL10641903 0.71 GSK3A (0.53) DDB1CRBNL3MBTL1F2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 DDB1 1117/4885CRBN 614/4885L3MBTL1 2080/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 DDB1 1117/4885CRBN 614/4885L3MBTL1 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.